In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potential game-changer. Initially ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

Fact checked by Nick Blackmer Some anti-obesity medications, including GLP-1s, may prompt people to drink less alcohol, new ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...